Publication Year

Fergie J, Gonzales T, Suh M, Jiang X, Fryzek JP, Hooda N, Howard A, Bloomfield A. Higher-risk congenital heart disease (CHD) among children aged ≤24 months with respiratory syncytial virus hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH). 37th Annual Children’s National Symposium: ECMO and the Advanced Therapies for Cardiovascular and Respiratory Failure, February 2021.

Wikoff DS, Urban JD, Ring C, Britt J, Fitch S, Haws LC. 2021. Development of a range of plausible non-cancer toxicity values for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) based on effects on sperm count: Application of systematic review methods and quantitative integration of dose response using meta-regression. Toxicol Sci 179(2):162-182; doi: 10.1093/toxsci/kfaa171. PMID: 33306106.

Thompson CM, Bhat VS, Brorby GP, Haws LC. 2021. Development of updated RfD and RfC values for medium carbon range aromatic and aliphatic total petroleum hydrocarbon fractions. J Air Waste Manag Assoc 71(12):1555–1567; doi: 10.1080/10962247.2021.1974123. PMID: 34469276.

Chappell GA, Wikoff DS, Thompson CM. 2021. Assessment of mechanistic data for hexavalent chromium-induced rodent intestinal cancer using the key characteristics of carcinogens. Toxicol Sci 180(1):38–50; doi: 10.1093/toxsci/kfaa187. PMID: 33404626.

Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA, Cronin M, Djulbegovic B,…, Patlewicz G, et al. 2021. GRADE Guidelines 30: The GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making. J Clin Epidemiol 129(Jan):138-150; doi: 101016/j.jclinepi.2020.09.018. PMID: 32980429.

Rovida C, Escher SE, Herzler M, Bennekou SH, Kamp H, Kroese DE, Maslankiewicz L, Moné MJ, Patlewicz G, et al. 2021. NAM-supported read-across: From case studies to regulatory guidance in safety assessment. ALTEX 38(1):140-150; doi: 10.14573/altex.2010062. PMID: 33452529.

Chappell GA, Heintz MM, Haws LC. 2021. Transcriptomic analyses of livers from mice exposed to 1,4-dioxane for up to 90 days to assess potential mode(s) of action underlying liver tumor development. Curr Res Toxicol 2:30–41; doi: 10.1016/j.crtox.2021.01.003. PMID: 34345848.